JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Q.
Right arrow Articles by Van De Kar, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Q.
Right arrow Articles by Van De Kar, L. D.

Vol. 282, Issue 3, 1581-1590, 1997

A Desensitization of Hypothalamic 5-HT1A Receptors by Repeated Injections of Paroxetine: Reduction in the Levels of Gi and Go Proteins and Neuroendocrine Responses, but Not in the Density of 5-HT1A Receptors1

Q. Li2, N. A. Muma, G. Battaglia and L. D. Van De Kar

Department of Pharmacology, Stritch School of Medicine, Loyola University Chicago, Maywood Illinois

The aim of the present study was to determine whether the previously observed desensitization of hypothalamic 5-hydroxytryptamine1A (5-HT1A) receptors, during daily injections of fluoxetine, is mediated by sustained blockade of 5-HT reuptake. In the present study, we examined the time course effects of another 5-HT uptake inhibitor, paroxetine. Paroxetine reduced the oxytocin, adrenal corticotropic hormone and corticosterone responses to a challenge with the 5-HT1A agonist 8-hydroxy-2-(dipropylamino)tetralin. These reductions in hormone responses were significant after 3 daily injections and reached a maximum after 7 daily paroxetine injections. These hormone responses remained maximally suppressed after 14 daily injections of paroxetine. A single day of paroxetine treatment did not alter the hormone responses to 8-hydroxy-2-(dipropylamino)tetralin. Repeated injections of paroxetine did not reduce the density of 5-HT1A receptors in any brain region but did produce a gradual reduction in the levels of Gi and Go proteins in a region-specific manner. The time course of the paroxetine-induced reduction in the level of Gi1 and Gi3 proteins in the hypothalamus was similar to the effect previously observed with fluoxetine and was also similar to the time course of paroxetine-induced reductions in oxytocin and adrenal corticotropic hormone responses to 8-hydroxy-2-(dipropylamino)tetralin. In conclusion, these results suggest that blockade of 5-HT uptake sites produces a delayed and gradual desensitization of 5-HT1A receptors in the hypothalamus. This desensitization is not due to changes in the density of hypothalamic 5-HT1A receptors. Reduction in the hypothalamic level of Gi3 proteins may play a role in the desensitization of 5-HT1A receptor systems. However, reductions in Gi1 or Go proteins cannot be excluded as potential mediators of the desensitization of 5-HT1A receptor systems.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
G. A. Carrasco, L. D. Van de Kar, C. Jia, H. Xu, Z. Chen, R. Chadda, F. Garcia, N. A. Muma, and G. Battaglia
Single Exposure to a Serotonin 1A Receptor Agonist, (+)8-Hydroxy-2-(di-n-propylamino)-tetralin, Produces a Prolonged Heterologous Desensitization of Serotonin 2A Receptors in Neuroendocrine Neurons in Vivo
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1078 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. M. la Cour, S. El Mestikawy, N. Hanoun, M. Hamon, and L. Lanfumey
Regional Differences in the Coupling of 5-Hydroxytryptamine-1A Receptors to G Proteins in the Rat Brain
Mol. Pharmacol., September 1, 2006; 70(3): 1013 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Corradetti, B. Mlinar, C. Falsini, A. M. Pugliese, A. Cilia, C. Destefani, and R. Testa
Differential Effects of the 5-Hydroxytryptamine (5-HT)1A Receptor Inverse Agonists Rec 27/0224 and Rec 27/0074 on Electrophysiological Responses to 5-HT1A Receptor Activation in Rat Dorsal Raphe Nucleus and Hippocampus in Vitro
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 109 - 117.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Zhang, T. S. Gray, D. N. D'Souza, G. A. Carrasco, K. J. Damjanoska, B. Dudas, F. Garcia, G. M. Zainelli, N. R. Sullivan Hanley, G. Battaglia, et al.
Desensitization of 5-HT1A Receptors by 5-HT2A Receptors in Neuroendocrine Neurons in Vivo
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 59 - 66.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. J. Damjanoska, B. A. Heidenreich, G. H. Kindel, D. N. D'Souza, Y. Zhang, F. Garcia, G. Battaglia, W. A. Wolf, L. D. Van de Kar, and N. A. Muma
Agonist-Induced Serotonin 2A Receptor Desensitization in the Rat Frontal Cortex and Hypothalamus
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1043 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. N. D'Souza, Y. Zhang, F. Garcia, G. Battaglia, and L. D. Van de Kar
Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R390 - R397.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. J. Damjanoska, L. D. Van de Kar, G. H. Kindel, Y. Zhang, D. N. D'Souza, F. Garcia, G. Battaglia, and N. A. Muma
Chronic Fluoxetine Differentially Affects 5-Hydroxytryptamine2A Receptor Signaling in Frontal Cortex, Oxytocin- and Corticotropin-Releasing Factor-Containing Neurons in Rat Paraventricular Nucleus
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 563 - 571.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. J. Damjanoska, N. A. Muma, Y. Zhang, D. N. D'Souza, F. Garcia, G. A. Carrasco, G. H. Kindel, K. A. Haskins, M. Shankaran, B. R. Petersen, et al.
Neuroendocrine Evidence That (S)-2-(Chloro-5-fluoro-indol- l-yl)-1-methylethylamine Fumarate (Ro 60-0175) Is Not a Selective 5-Hydroxytryptamine2C Receptor Agonist
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1209 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Y. Zhang, K. J. Damjanoska, G. A. Carrasco, B. Dudas, D. N. D'Souza, J. Tetzlaff, F. Garcia, N. R. S. Hanley, K. Scripathirathan, B. R. Petersen, et al.
Evidence That 5-HT2A Receptors in the Hypothalamic Paraventricular Nucleus Mediate Neuroendocrine Responses to (-)DOI
J. Neurosci., November 1, 2002; 22(21): 9635 - 9642.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Newman-Tancredi, D. Cussac, L. Marini, and M. J. Millan
Antibody Capture Assay Reveals Bell-Shaped Concentration-Response Isotherms for h5-HT1A Receptor-Mediated Galpha i3 Activation: Conformational Selection by High-Efficacy Agonists, and Relationship to Trafficking of Receptor Signaling
Mol. Pharmacol., September 1, 2002; 62(3): 590 - 601.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Y. Zhang, D. D'Souza, D. K. Raap, F. Garcia, G. Battaglia, N. A. Muma, and L. D. Van de Kar
Characterization of the Functional Heterologous Desensitization of Hypothalamic 5-HT1A Receptors after 5-HT2A Receptor Activation
J. Neurosci., October 15, 2001; 21(20): 7919 - 7927.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
L. D. Van de Kar, A. Javed, Y. Zhang, F. Serres, D. K. Raap, and T. S. Gray
5-HT2A Receptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells
J. Neurosci., May 15, 2001; 21(10): 3572 - 3579.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Gobbi, D. L. Murphy, K.-P. Lesch, and P. Blier
Modifications of the Serotonergic System in Mice Lacking Serotonin Transporters: An in Vivo Electrophysiological Study
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 987 - 995.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
Q. Li, C. Wichems, A. Heils, K.-P. Lesch, and D. L. Murphy
Reduction in the Density and Expression, But Not G-Protein Coupling, of Serotonin Receptors (5-HT1A) in 5-HT Transporter Knock-Out Mice: Gender and Brain Region Differences
J. Neurosci., November 1, 2000; 20(21): 7888 - 7895.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Serres, N. A. Muma, D. K. Raap, F. Garcia, G. Battaglia, and L. D. Van de Kar
Coadministration of 5-Hydroxytryptamine1A Antagonist WAY-100635 Prevents Fluoxetine-Induced Desensitization of Postsynaptic 5-Hydroxytryptamine1A Receptors in Hypothalamus
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 296 - 301.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
F. Serres, Q. Li, F. Garcia, D. K. Raap, G. Battaglia, N. A. Muma, and L. D. Van de Kar
Evidence That Gz-Proteins Couple to Hypothalamic 5-HT1A Receptors In Vivo
J. Neurosci., May 1, 2000; 20(9): 3095 - 3103.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
P. A. Sargent, K. H. Kjaer, C. J. Bench, E. A. Rabiner, C. Messa, J. Meyer, R. N. Gunn, P. M. Grasby, and P. J. Cowen
Brain Serotonin1A Receptor Binding Measured by Positron Emission Tomography With [11C]WAY-100635: Effects of Depression and Antidepressant Treatment
Arch Gen Psychiatry, February 1, 2000; 57(2): 174 - 180.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Q. Li, C. Wichems, A. Heils, L. D. Van de Kar, K.-P. Lesch, and D. L. Murphy
Reduction of 5-Hydroxytryptamine (5-HT)1A-Mediated Temperature and Neuroendocrine Responses and 5-HT1A Binding Sites in 5-HT Transporter Knockout Mice
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 999 - 1007.
[Abstract] [Full Text]

Home page
 Psychosom. Med.Home page
G. Chen, K. A. Hasanat, J. M. Bebchuk, G. J. Moore, D. Glitz, and H. K. Manji
Regulation of Signal Transduction Pathways and Gene Expression by Mood Stabilizers and Antidepressants
Psychosom Med, September 1, 1999; 61(5): 599 - 617.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. K. Raap, F. Garcia, N. A. Muma, W. A. Wolf, G. Battaglia, and L. D. van de Kar
Sustained Desensitization of Hypothalamic 5-Hydroxytryptamine1A Receptors after Discontinuation of Fluoxetine: Inhibited Neuroendocrine Responses to 8-Hydroxy-2-(Dipropylamino)Tetralin in the Absence of Changes in Gi/o/z Proteins
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 561 - 567.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. K. Raap, S. Evans, F. Garcia, Q. Li, N. A. Muma, W. A. Wolf, G. Battaglia, and L. D. Van De Kar
Daily Injections of Fluoxetine Induce Dose-Dependent Desensitization of Hypothalamic 5-HT1A Receptors: Reductions in Neuroendocrine Responses to 8-OH-DPAT and in Levels of Gz and Gi Proteins
J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 98 - 106.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. D. V. d. Kar, Q. Li, T. M. Cabrera, M. S. Brownfield, and G. Battaglia
Alterations in 8-Hydroxy-2-(dipropylamino)tetralin-Induced Neuroendocrine Responses after 5,7-Dihydroxytryptamine-Induced Denervation of Serotonergic Neurons
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 256 - 262.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.